Antigen News and Research

RSS

Preoperative radiation boosts immunotherapy response in brain metastases

A new study led by researchers at The University of Texas MD Anderson Cancer Center demonstrated that pre-operative radiation therapy for brain metastases not only targets tumor cells directly but also can activate immune pathways that can make tumors more receptive to immunotherapy.

17 Jun 2026

Study finds gaps in guideline-based testosterone prescribing practices

Only a small number of men who were prescribed testosterone therapy received appropriate, guideline-concordant diagnostic testing, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill, by Sophia Sinha, M.D., clinical assistant professor at the University of Michigan in Ann Arbor, Mich.

14 Jun 2026

Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering

The University of Oklahoma has received an $11.5 million award from the National Institutes of Health to establish the Oklahoma Center of ImmunoEngineering, a new research center designed to accelerate the study and treatment of diseases rooted in the immune system.

12 Jun 2026

Review outlines virtual tumor concept and next-generation immunotherapy

A comprehensive review led by Associate Researcher Linnan Zhu and Academician Zemin Zhang at Biomedical Pioneering Innovation Center (BIOPIC), Peking University, China, and Chongqing Medical University, China, was published in Volume 2, article number 27 of the journal Immunity & Inflammation on June 05, 2026.

12 Jun 2026

Researchers uncover immune loop driving Sjögren's disease progression

Sjögren's disease is a widespread chronic autoimmune disorder that attacks the body's own glands, yet its underlying disease mechanisms remain poorly understood.

10 Jun 2026

Why Andes hantavirus is not the next COVID-19

Research highlights fundamental differences between Andes hantavirus and SARS-CoV-2, emphasizing distinct transmission routes and public health implications.

10 Jun 2026

NYU Langone hits milestone with its 1,000th focal cryotherapy procedure

Just two days after his minimally invasive prostate cancer treatment at NYU Langone Health, Broadway performer André De Shields, 80, was back onstage preparing for his next show, Cats: The Jellicle Ball, which debuted in April 2026.

5 Jun 2026

Universal Sarbeco coronavirus vaccine proves safe in first human trial

The first human clinical trial of a universal Sarbeco coronavirus vaccine, developed by the University of Cambridge and spin-out DIOSynVax (DVX) Ltd, has shown that the vaccine is safe and has no significant side-effects.

4 Jun 2026

Microglia transitions act as critical turning point in Alzheimer's

Researchers from VIB, KU Leuven, the UK-DRI and Muna Therapeutics, funded by, among others, ERC, have uncovered a critical biological transition that may determine whether Alzheimer's disease pathology leads to dementia.

4 Jun 2026

Repurposed cancer therapy enables successful kidney transplantation

A pioneering clinical trial has successfully enabled three patients with end-stage kidney disease to receive previously improbable kidney transplants.

4 Jun 2026

Case report highlights diagnostic features of rare eyelid sebaceous adenoma

A new case report was published in Volume 13 of Oncoscience on April 2, 2026, titled "Sebaceous adenoma of the eyelid: A clinical, histopathological, and immunohistochemical perspective."

4 Jun 2026

Researchers discover a biological barrier that limits mucosal vaccine immunity

A consistent biological barrier that stops the immune system from making the antibodies most needed to protect the nose and throat from respiratory viruses has been identified.

4 Jun 2026

Novel CAR T treatment makes previously impossible kidney transplants possible

A pioneering clinical trial has successfully enabled two patients with end-stage kidney disease to receive previously improbable kidney transplants.

3 Jun 2026

CAR-T cell therapy shows promise for treating rheumatoid arthritis

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

3 Jun 2026

Novel theranostic approach targets aggressive neuroendocrine prostate cancer

A novel theranostic approach that targets RET -- a newly identified biomarker for neuroendocrine prostate cancer enables high-contrast PET imaging and effective, safe treatment for this highly aggressive malignancy.

2 Jun 2026

Pediatric experts reveal the 10 research areas set to shape child health

Pediatric research leaders identified 10 high-promise areas likely to shape child health over the next 5 to 10 years, including genomics, mental health, vaccines, artificial intelligence, perinatal medicine, precision therapeutics, health equity, nutrition, environmental health, and cancer treatment. The paper argues that these opportunities will only translate into better outcomes if pediatric research receives sustained funding, public trust, workforce support, advocacy, and equitable implementation.

1 Jun 2026

Laverock Therapeutics awarded in excess of £2.2 M through two innovation grants to support AI-powered platform development and to expand therapeutic programs outside of oncology

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced it has been awarded two new grants totaling in excess of £2.2 M to support the next generation of its gene-control platform development, and expansion into additional non-oncology therapeutics areas.

From Laverock Therapeutics 1 Jun 2026

PSMA PET detects high-risk prostate cancer bone metastases

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior detection of bone metastases in prostate cancer patients a critical indicator of a patient's long-term survival.

1 Jun 2026

Hypoxia-gated AAV enables targeted treatment for advanced NSCLC

Adeno‑associated virus (AAV) vectors offer safety and durable expression but lack tumor specificity. This hypothesis proposes an NSCLC‑directed, hypoxia‑responsive AAV platform that integrates MGS4 peptide‑guided capsid targeting with dual hypoxia‑responsive element (HRE)‑gated promoters driving Q‑CXCL9‑Fc (chemokine) and miR‑30‑based shRNA against mesothelin (MSLN).

1 Jun 2026

New T-cell engager therapy shows effectiveness in advanced solid tumors

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors.

1 Jun 2026